Effect of S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine
Status: | Completed |
---|---|
Conditions: | Metabolic |
Therapuetic Areas: | Pharmacology / Toxicology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/17/2018 |
Start Date: | August 2009 |
End Date: | July 2013 |
Effect of Oral S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine in Human Subjects
The purpose of this study is to investigate whether S-adenosylmethionine (SAMe), a natural
substance available as a nutritional supplement, can influence blood levels of homocysteine
(Hcy). More specifically, we will determine if chronic oral SAMe administration affects
homocysteine metabolism in patients with vascular disease who have mild to moderate
hyperhomocysteinemia.
substance available as a nutritional supplement, can influence blood levels of homocysteine
(Hcy). More specifically, we will determine if chronic oral SAMe administration affects
homocysteine metabolism in patients with vascular disease who have mild to moderate
hyperhomocysteinemia.
The purpose of this study is to investigate whether S-adenosylmethionine (SAMe), a natural
substance available as a nutritional supplement, can influence blood levels of homocysteine
(Hcy). More specifically, we will determine if chronic oral SAMe administration effects
homocysteine metabolism in patients with vascular disease who have mild to moderate
hyperhomocysteinemia through the following specific aims:
Specific Aim 1 - To determine the effect of oral SAMe (1200 mg/day) on plasma total
homocysteine levels in subjects with mild to moderate hyperhomocysteinemia.
Specific Aim 2 - To determine the effect of oral SAMe (1200 mg/day) with and without
supplementation of folate, vitamin B12 and B6, on plasma homocysteine levels in patients with
mild to moderate hyperhomocysteinemia.
Specific Aim 3 - To determine the effect of oral SAMe (1200 mg/day) on plasma levels pf
asymmetric dimethylarginine (ADMA) in subjects with mild to moderate hyperhomocysteinemia.
substance available as a nutritional supplement, can influence blood levels of homocysteine
(Hcy). More specifically, we will determine if chronic oral SAMe administration effects
homocysteine metabolism in patients with vascular disease who have mild to moderate
hyperhomocysteinemia through the following specific aims:
Specific Aim 1 - To determine the effect of oral SAMe (1200 mg/day) on plasma total
homocysteine levels in subjects with mild to moderate hyperhomocysteinemia.
Specific Aim 2 - To determine the effect of oral SAMe (1200 mg/day) with and without
supplementation of folate, vitamin B12 and B6, on plasma homocysteine levels in patients with
mild to moderate hyperhomocysteinemia.
Specific Aim 3 - To determine the effect of oral SAMe (1200 mg/day) on plasma levels pf
asymmetric dimethylarginine (ADMA) in subjects with mild to moderate hyperhomocysteinemia.
Inclusion Criteria:
- 18 years of age and older
- Must have a serum homocysteine value greater than or equal to 14 μmol/L
- Stable weight 3 months prior to study participation
Exclusion Criteria:
- Subjects with a BMI greater than 35 or less than 18
- Currently taking B 100 or other high-dose B vitamin supplements within the past 12
months
- Taken methionine or SAMe supplements within the past 3 months
We found this trial at
1
site
Baylor University Medical Center Baylor University Medical Center in Dallas, TX is ranked nationally in...
Click here to add this to my saved trials